$Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept$

Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept

<i>Background and Objectives</i>: Faricimab is the first intravitreal injection of vascular endothelial growth factor-A and angiopoietin-2 bispecific monoclonal antibody. Here, we evaluate the functional and anatomical outcomes of faricimab treatment in patients with diabetic macular ede...

Full description

Bibliographic Details
Main Authors:	Hiromi Ohara, Yosuke Harada, Tomona Hiyama, Ayako Sadahide, Akira Minamoto, Yoshiaki Kiuchi
Format:	Article
Language:	English
Published:	MDPI AG 2023-06-01
Series:	Medicina
Subjects:	diabetic macular edema faricimab ranibizumab aflibercept vascular endothelial growth factor angiopoietin-2
Online Access:	https://www.mdpi.com/1648-9144/59/6/1125

Similar Items

Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review
by: Sławomir Liberski, et al.
Published: (2022-08-01)

Efficacy of Aflibercept versus Ranibizumab in the treatment of diabetic macular edema
by: Xiu-Xian Wang, et al.
Published: (2021-12-01)

One Year Results of Faricimab for Aflibercept-Resistant Diabetic Macular Edema
by: Rush RB
Published: (2023-08-01)

Comparative study between ranibizumab and aflibercept in the management of macular edema caused by diabetes mellitus in age group more than 40 years
by: Abd El-Magid M Tag El-Din
Published: (2019-01-01)

Efficacy of Aflibercept and Ranibizumab in the treatment of diabetic macular edema
by: Bing Wu, et al.
Published: (2023-08-01)

Ranibizumab versus Aflibercept in Macular Edema Secondary to Retinal Vein Occlusion in Real Life: A Retrospective Case Control Study
by: Abdullah Özkaya, et al.
Published: (2017-05-01)

Short-Term Outcomes of Intravitreal Faricimab Injection for Diabetic Macular Edema
by: Sentaro Kusuhara, et al.
Published: (2023-03-01)

Comparison between the Effect of Aflibercept (Eylea) and Ranibizumab (Lucentis) on Intraocular Pressure after 3rd Injection in Treatment of Diabetic Macular Edema
by: Hossam El Deen Khalil, et al.
Published: (2022-07-01)

Faricimab for Treatment-Resistant Diabetic Macular Edema
by: Rush RB, et al.
Published: (2022-08-01)

Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME
by: Fernando M Penha, et al.
Published: (2024-01-01)

A Real-Life Study: Intravitreal Aflibercept, Ranibizumab and Dexamethasone for Macular Edema Secondary to Branch Retinal Vein Occlusion
by: Alper Halil Bayat, et al.
Published: (2019-12-01)

Comparison of Loading Dose between Aflibercept and Faricimab for Neovascular Age-Related Macular Degeneration
by: Chikako Hara, et al.
Published: (2024-01-01)

Comparison of 2-Year Outcomes between Intravitreal Ranibizumab and Intravitreal Aflibercept for Diabetic Macular Edema with “Treat-and-Extend” Regimen—Its Usefulness and Problems
by: Shinichiro Chujo, et al.
Published: (2020-09-01)

Ranibizumab or Aflibercept Monotherapies in Treatment-Naive Eyes with Diabetic Macular Edema: A Head-to-Head Comparison in Real-Life Experience
by: Mahmut Kaya, et al.
Published: (2023-02-01)

Short-Term Outcomes of Faricimab Treatment in Aflibercept-Refractory Eyes with Neovascular Age-Related Macular Degeneration
by: Maya Kishi, et al.
Published: (2023-08-01)

Rationale and Design of VOYAGER: Long-term Outcomes of Faricimab and Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in Clinical Practice
by: Robyn Guymer, MBBS, PhD, et al.
Published: (2024-05-01)

Evaluation of contrast sensitivity and other visual function outcomes in diabetic macular edema patients following treatment switch to aflibercept from ranibizumab
by: Nixon DR, et al.
Published: (2018-01-01)

Does HbA1c Level or Glomerular Filtration Rate Affect the Clinical Response to Endothelial Growth Factor Therapy (Ranibizumab or Aflibercept) in Diabetic Macular Edema? A Real-Life Experience
by: Eloi Debourdeau, et al.
Published: (2023-07-01)

Aflibercept monotherapy or bevacizumab first for diabetic macular edema
by: Avner Hostovsky, et al.
Published: (2024-01-01)

Research progress of novel bispecific monoclonal antibody Faricimab in the treatment of diabetic macular edema and age-related macular degeneration
by: Xin-Li Wei, et al.
Published: (2023-10-01)

Comparison of efficacy of conbercept, aflibercept, and ranibizumab ophthalmic injection in the treatment of macular edema caused by retinal vein occlusion: a Meta-analysis
by: Qiu Xing, et al.
Published: (2023-07-01)

Visual and Anatomical Outcomes After Initial Intravitreal Faricimab Injection for Neovascular Age-Related Macular Degeneration in Patients with Prior Treatment History
by: Satoru Inoda, et al.
Published: (2023-08-01)

BALATON and COMINO: Phase III Randomized Clinical Trials of Faricimab for Retinal Vein Occlusion
by: Lars-Olof Hattenbach, MD, PhD, et al.
Published: (2023-09-01)

Short-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab
by: Sakanishi Y, et al.
Published: (2017-05-01)

Ranibizumab versus aflibercept for macular edema secondary to nonischemic central retinal vein occlusion in young adult patients
by: Ahmed A Amer, et al.
Published: (2022-01-01)

Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
by: Koike N, et al.
Published: (2019-07-01)

Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema
by: Alsaedi NG, et al.
Published: (2021-07-01)

Effect of repeated intravitreal Ranibizumab and Aflibercept injections on the corneal nerves in patients with macular edema
by: Yuan-Yuan Qi, et al.
Published: (2023-05-01)

Intravitreal Aflibercept Therapy in Intravitreal Bevacizumab/Ranibizumab Treatment-resistant Exudative Age-related Macular Degeneration
by: Neslihan Sevimli, et al.
Published: (2023-09-01)

Intravitreal Faricimab for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
by: Rush RB, et al.
Published: (2022-12-01)

Efficacy of intravitreal injection of Aflibercept vs Ranibizumab in the treatment of diabetic retinopathy
by: Chang Huang, et al.
Published: (2021-05-01)

Switching to ziv-aflibercept in resistant diabetic macular edema non responsive to ranibizumab injection
by: Amin E. Nawar, et al.
Published: (2022-06-01)

Comparison of the efficacy of intravitreal Anti-VEGF versus intravitreal dexamethasone implant in treatment resistant diabetic Macular Edema
by: Hakan Koc, et al.
Published: (2023-03-01)

Aflibercept compared with dexamethasone in diabetic macular edema
by: Rodolfo Garretón, et al.
Published: (2021-05-01)

Short-Term Outcomes of Switching to Ranibizumab in Polypoidal Choroidal Vasculopathy Resistant to Aflibercept Therapy
by: Young-Joon Jeon, et al.
Published: (2021-12-01)

Effect of intravitreal aflibercept on recalcitrant diabetic macular edema
by: Kendra A. Klein, et al.
Published: (2017-04-01)

Contralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema
by: Thomas BJ, et al.
Published: (2016-08-01)

INTRAVITREAL RANIBIZUMAB FOR THE TREATMENT OF MACULAR EDEMA SECONDARY TO MALIGNANT HYPERTENSION
by: Raquel Claro Brito, et al.
Published: (2016-01-01)

One-Year Outcomes of Faricimab Treatment for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
by: Rush RB
Published: (2023-08-01)

Real-World Results of Switching Treatment from Ranibizumab to Aflibercept in Macular Oedema Secondary to Branch Retinal Vein Occlusion
by: Vasileios E. Konidaris, et al.
Published: (2018-10-01)